REFRACTORY WHO GRADE 2 GLIOMA
Clinical trials for REFRACTORY WHO GRADE 2 GLIOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY WHO GRADE 2 GLIOMA trials appear
Sign up with your email to follow new studies for REFRACTORY WHO GRADE 2 GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets genetic flaw in Kids' Tough-to-Treat cancers
Disease control OngoingThis study is testing an oral medication called tipifarnib in children and young adults (ages 1-21) whose advanced solid tumors, lymphoma, or histiocytic disorders have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control t…
Matched conditions: REFRACTORY WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 09:21 UTC
-
New hope for kids with tough cancers: trial tests precision drug
Disease control OngoingThis study is testing how well a drug called selpercatinib works for children and young adults with advanced or hard-to-treat cancers that have a specific genetic change in the RET gene. The drug is designed to block the growth of cancer cells with this change. Participants take …
Matched conditions: REFRACTORY WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope for kids with tough cancers: drug targets genetic flaw
Disease control OngoingThis study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…
Matched conditions: REFRACTORY WHO GRADE 2 GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC